Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.
HER2 positive
access
breast cancer
neoadjuvant
pertuzumab
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
16 12 2022
16 12 2022
Historique:
received:
17
11
2022
revised:
30
11
2022
accepted:
10
12
2022
entrez:
22
12
2022
pubmed:
23
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
The addition of pertuzumab to neoadjuvant trastuzumab and chemotherapy for women with early-stage, high-risk, HER2+ breast cancer has been observed to lead to higher pathologic complete response rates (pCR), and improved event-free survival compared to trastuzumab and chemotherapy alone. Based on available data, neoadjuvant pertuzumab is recommended by ESMO, ASCO, and NICE as well as by a Canadian Consensus Guideline Group. We discuss the implications for Canadian patients with HER2+ early breast cancer due to a second and final negative funding decision by the Canadian Agency for Drugs and Technologies in Health (CADTH) related to neoadjuvant pertuzumab. This decision will have adverse impacts for up to 1 in 6 women receiving neoadjuvant therapy for high-risk HER2+ breast cancer, due to suboptimal pCR rates and higher risks of invasive breast cancer recurrent events, resulting in the need for more toxic adjuvant therapy.
Identifiants
pubmed: 36547192
pii: curroncol29120778
doi: 10.3390/curroncol29120778
pmc: PMC9777307
doi:
Substances chimiques
pertuzumab
K16AIQ8CTM
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9891-9895Références
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
J Clin Oncol. 2010 Jan 20;28(3):509-18
pubmed: 19949017
Lancet Oncol. 2022 Jan;23(1):149-160
pubmed: 34902335
Ann Oncol. 2021 Oct;32(10):1216-1235
pubmed: 34242744
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
Breast Cancer Res Treat. 2022 May;193(1):1-20
pubmed: 35224713
J Clin Oncol. 2021 May 1;39(13):1485-1505
pubmed: 33507815
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
J Clin Oncol. 2021 May 1;39(13):1448-1457
pubmed: 33539215
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Lancet Oncol. 2018 Dec;19(12):1630-1640
pubmed: 30413379
Lancet. 2012 Feb 18;379(9816):633-40
pubmed: 22257673
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
J Clin Oncol. 2008 Dec 10;26(35):5697-704
pubmed: 19001334
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
CMAJ. 2022 May 2;194(17):E601-E607
pubmed: 35500919